G
Giuseppe Palermo
Researcher at Hoffmann-La Roche
Publications - 14
Citations - 303
Giuseppe Palermo is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 7, co-authored 13 publications receiving 219 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease
Lauren M. Byrne,Filipe B. Rodrigues,Eileanoir B. Johnson,P. A. Wijeratne,Enrico De Vita,Daniel C. Alexander,Giuseppe Palermo,Christian Czech,Scott Schobel,Rachael I. Scahill,Amanda Heslegrave,Henrik Zetterberg,Edward J. Wild +12 more
TL;DR: In blood and cerebrospinal fluid, mutant huntingtin (mHTT) and neurofilament light (NfL) protein concentrations correlated with disease severity in HD patients and showed that alterations in circulating NfL and mHTT concentrations may be among the earliest detectable changes in HD.
Journal ArticleDOI
Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFα inhibitors in patients with rheumatoid arthritis.
Sophine B. Krintel,Giuseppe Palermo,Julia S. Johansen,Soren Germer,Laurent Essioux,Ryma Benayed,Laura Badi,Mikkel Østergaard,Merete Lund Hetland +8 more
TL;DR: No SNPs associated with treatment response to TNF&agr; inhibitors are found in a genome-wide association study of 196 genetically homogenous Danish patients with RA and in a meta-analysis of available studies.
Journal ArticleDOI
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients
Annika Dufour,Giuseppe Palermo,Evelyn Zellmeier,Gudrun Mellert,Guillemette Duchateau-Nguyen,Stephanie Schneider,Tobias Benthaus,Purvi M. Kakadia,Purvi M. Kakadia,Karsten Spiekermann,Wolfgang Hiddemann,Jan Braess,Sim Truong,Nancy Patten,Lin Wu,Sabine Lohmann,David Dornan,Debraj GuhaThakurta,Ru-Fang Yeh,Galina Salogub,Philippe Solal-Celigny,Anna Dmoszynska,Tadeusz Robak,Marco Montillo,John Catalano,Christian H. Geisler,Martin Weisser,Stefan K. Bohlander,Stefan K. Bohlander +28 more
TL;DR: A complete disruption of TP53 function, either by a combination of point mutations and/or del17p, was associated with a high risk for disease progression and progression-free survival of patients with a heterozygous TP53 mutation was not significantly different from patients with an completely intact TP53 locus.
Journal ArticleDOI
Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.
Wai Yin Yeung,Bruno Reigner,Ulrich Beyer,Cheikh Diack,Daniel Sabanés Bové,Giuseppe Palermo,Thomas Jaki +6 more
TL;DR: D dose-escalation designs that incorporate both the dose-limiting events and dose- Limiting toxicities (DLTs) and indicative responses of efficacy into the procedure are introduced.
Journal ArticleDOI
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Martin Weisser,Ru-Fang Yeh,Guillemette Duchateau-Nguyen,Giuseppe Palermo,Tri Quang Nguyen,Xiaoyan Shi,Susanna Stinson,Nancy Yu,Annika Dufour,Tadeusz Robak,Galina Salogub,Anna Dmoszynska,Philippe Solal-Celigny,Krzysztof Warzocha,Javier Loscertales,John Catalano,Loree Larratt,Viktor Rossiev,Isabelle Bence-Bruckler,Christian H. Geisler,Marco Montillo,Kirsten Fischer,Anna-Maria Fink,Michael Hallek,Johannes Bloehdorn,Raymonde Busch,Axel Benner,Hartmut Döhner,Nancy Valente,Michael Wenger,Stephan Stilgenbauer,David Dornan +31 more
TL;DR: Retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC, and may be a useful biomarker for patient selection in future trials.